4 research outputs found

    Les manifestations dentaires des maladies génétiques

    No full text
    Des anomalies peuvent survenir au cours des différentes étapes de l'odontogenèse qui concourent donc à entraver le bon développement dentaire. Ces anomalies peuvent affecter le nombre de dents présentes, leur structure, leur morphologie ou encore troubler leur éruption ou leur devenir sur l'arcade. L'étiologie de ces diverses manifestations dentaires peut être de différents types, variant de simples facteurs locaux à des anomalies systémiques. Ainsi, ces anomalies dentaires seront dites isolées ou associées dans des formes syndromiques qui seront le plus souvent d'origine génétique. Nous envisagerons dans ce travail une revue des différents syndromes génétiques qui associent des anomalies dentaires caractéristiques dans leur tableau clinique. Ainsi, nous montrerons l'importance du rôle du chirurgien-dentiste dans le dépistage de ces anomalies dentaires et dans la recherche d'éventuels autres signes associés.TOULOUSE3-BU Santé-Centrale (315552105) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

    FAK alternative splice mRNA variants expression pattern in colorectal cancer

    Get PDF
    International audienceThe Focal adhesion kinase (FAK) is a ubiquitous cytoplasmic tyrosine-kinase promoting tumor progression and metastasis processes by acting in cancer cells and their tumor microenvironment partners. FAK overexpression in primary colon tumors and their metastasis is associated to poor colorectal cancer (CRC) patients' outcome. Eight FAK mRNA alternative splice variants have been described and contribute to additional level of FAK activity regulation, some of them corresponding to overactivated FAK isoforms. To date, FAK mRNA alternative splice variants expression and implication in CRC processes remain unknown. Here, using different human CRC cells lines displaying differential invasive capacities in an in vivo murine model recapitulating the different steps of CRC development from primary tumors to liver and lung metastasis, we identified three out of the eight mRNA variants (namely FAK 0 , FAK 28 and FAK 6) differentially expressed along the CRC process and the tumor sites. Our results highlight an association between FAK 0 and FAK 6 expressions and the metastatic potential of the most aggressive cell lines HT29 and HCT116, suggesting that FAK 0 and FAK 6 could represent aggressiveness markers in CRC. Our findings also suggest a more specific role for FAK 28 in the interactions between the tumors cells and their microenvironment. In conclusion, targeting FAK 0 , the common form of FAK, might not be a good strategy based on the numerous roles of this kinase in physiological processes. In contrast, FAK 6 or FAK 28 splice variants, or their corresponding protein isoforms, may putatively represent future therapeutic target candidates in the development of CRC primary tumors and metastasis
    corecore